Short Interest in Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Expands By 42.9%

Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) was the recipient of a significant increase in short interest during the month of November. As of November 15th, there was short interest totalling 1,000 shares, an increase of 42.9% from the October 31st total of 700 shares. Based on an average daily trading volume, of 46,700 shares, the short-interest ratio is presently 0.0 days.

Emmaus Life Sciences Price Performance

EMMA stock remained flat at $0.03 during mid-day trading on Friday. 644 shares of the company’s stock traded hands, compared to its average volume of 34,302. The firm’s 50-day moving average price is $0.03 and its 200-day moving average price is $0.05. Emmaus Life Sciences has a 1-year low of $0.00 and a 1-year high of $0.14. The company has a market capitalization of $1.91 million, a P/E ratio of -0.33 and a beta of 6.50.

Emmaus Life Sciences (OTCMKTS:EMMA) last announced its quarterly earnings results on Tuesday, September 10th. The company reported ($0.03) EPS for the quarter. The company had revenue of $5.38 million during the quarter.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.